A Phase 1, Double-Masked, Randomized, Placebo-Controlled, Single Ascending Dose Crossover Study to Assess the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous DT-216P2 in Normal Healthy Participants
Latest Information Update: 11 Mar 2025
At a glance
Most Recent Events
- 10 Mar 2025 According to a Design Therapeutics media release, company has initiated dosing in a Phase 1 clinical trial in healthy volunteers in Australia.
- 10 Mar 2025 Status changed from not yet recruiting to recruiting.
- 21 Feb 2025 Planned End Date changed from 1 Sep 2025 to 1 Dec 2025.